



Summary

Sparsha Pharma USA, Inc. is a pharmaceutical manufacturing company located in Oceanside, CA. Sparsha specializes in developing and manufacturing film products such as transdermal patches, topical patches, and oral and sublingual films for a wide range of medical needs, with an emphasis on patient and environmental wellbeing.

Our Mission

To develop and produce safe, clinically effective, innovative, and affordable Transdermal, Sublingual and Topical delivery products to improve patient quality of life.

Services

- CMO (GMP Production Services)
- CRO (GMP Analytical Services)
- Private Label Manufacturing
- Product Stability Storing and Testing Services

Capabilities

- Formulation R&D for patch/oral films
- Process/Analytical Methods Development
- Manufacturing Scaleup
- FDA, DEA
- OTC, Prescription
- Manufacturing of Patches (Lidocaine 4% 24Hrs)

Our Company

Sparsha Pharma USA, Inc.
3919 Oceanic Dr.
Oceanside, CA 92056-5856
760-849-8160
844-348-5423 (toll free)
760-231-7198 (fax)
www.sparshausa.com
DUNS
079365856

Our Product



Certifications

SAM Cage # 8SHK6
DEA Research License
DEA Manufacturing License
California State Sellers Permit
FDA Establishment Identifier
Oceanside Business License
State of California Department of
Public Health Food and Drug Branch
Manufacturing License
NSF GMP Certificate – OTC Drugs

Our History

Dange Veerapaneni Ph.D. is the Chief Executive Officer of Sparsha Pharma USA, Inc. He started his career as a scientist with Japan based transdermal company in 1993. Over the next decade, he advanced through positions of increasing responsibility, culminating in being named General Manager of the company. Under his direct leadership, the company obtained FDA approval for a Fentanyl patch. Dange holds a Ph.D. in Molecular Biology from the University of India.

Nori Kuzumaki is the Chief Technology Officer of Sparsha Pharma USA, Inc. He started his career as a research scientist with Japan based transdermal company in 1994. Over the next two decades, he advanced through positions of increasing responsibility, in pharmaceutical formulation development, manufacturing process scale up, designing of production equipment and establishing production line, FDA submissions and compliance. Nori holds a Master of Engineering Polymer Science from Shinshu University, Japan.

With the idea of providing patients with cost-effective medication, in 2008 Dange and Nori founded Sparsha Pharma International Pvt, Ltd. (Sparsha India) later in 2015 Sparsha Pharma USA, Inc. recruiting Nori as his CTO for the company.

Under Dange's leadership, Sparsha India has developed and produces seven different drug products (18 SKUs) currently in the market and Sparsha Pharma USA, Inc. has started developing multiple products including transdermal patches, topical delivery patches, oral films and sublingual films for different applications. Lidocaine 4% Patch (Niravi 24 Hours) is the first product for Sparsha Pharma USA, Inc., and it is currently available in the market.